ID | 114665 |
Title Alternative | セレコキシブによるFKBP5を介したPD-L1の発現低下は, 悪性神経膠腫モデルにおける抗PD-1抗体医薬による抗腫瘍効果を増強する
FKBP5 regulation on anti-PD-1 therapy
|
Author |
Nakajima, Kohei
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Shono, Kenji
Tokushima University
Shikata, Eiji
Tokushima University
Yamaguchi, Tadashi
Tokushima University
Kitazato, Keiko
Tokushima University
Sampetrean, Oltea
Keio University
Saya, Hideyuki
Keio University
|
Keywords | glioblastoma
PD-1
PD-L1
FKBP5
celecoxib
|
Content Type |
Thesis or Dissertation
|
Description | Background. Antitumor therapies targeting programmed cell death-1 (PD-1) or its ligand-1 (PD-L1) are used in various cancers. However, in glioblastoma (GBM), the expression of PD-L1 varies between patients, and the relationship between this variation and the efficacy of anti-PD-1 antibody therapy remains unclear. High expression levels of PD-L1 affect the proliferation and invasiveness of GBM cells. As COX-2 modulates PD-L1 expression in cancer cells, we tested the hypothesis that the COX-2 inhibitor celecoxib potentiates anti-PD-1 antibody treatment via the downregulation of PD-L1.
Methods. Six-week-old male C57BL/6 mice injected with murine glioma stem cells (GSCs) were randomly divided into four groups treated with vehicle, celecoxib, anti-PD-1 antibody, or celecoxib plus anti-PD-1 antibody and the antitumor effects of these treatments were assessed. To verify the mechanisms underlying these effects, murine GSCs and human GBM cells were studied in vitro. Results. Compared with that with each single treatment, the combination of celecoxib and anti-PD-1 antibody treatment significantly decreased tumor volume and prolonged survival. The high expression of PD-L1 was decreased by celecoxib in the glioma model injected with murine GSCs, cultured murine GSCs, and cultured human GBM cells. This reduction was associated with post-transcriptional regulation of the co-chaperone FK506-binding protein 5 (FKBP5). Conclusions. Combination therapy with anti-PD-1 antibody plus celecoxib might be a promising therapeutic strategy to target PD-L1 in glioblastoma. The downregulation of highly-expressed PD-L1 via FKBP5, induced by celecoxib, could play a role in its antitumor effects. |
Journal Title |
Neuro-Oncology Advances
|
ISSN | 26322498
|
Publisher | Oxford University Press|the Society for Neuro-Oncology|the European Association of Neuro-Oncology
|
Volume | 2
|
Issue | 1
|
Start Page | vdz058
|
Published Date | 2019-12-26
|
Remark | 内容要旨・審査要旨・論文本文の公開
本論文は, 著者Izumi Yamaguchiの学位論文として提出され, 学位審査・授与の対象となっている。 |
Rights | © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
ETD
|
MEXT report number | 甲第3370号
|
Diploma Number | 甲医第1453号
|
Granted Date | 2020-03-23
|
Degree Name |
Doctor of Medical Science
|
Grantor |
Tokushima University
|
departments |
University Hospital
Medical Sciences
|